EXP016
/ Excalipoint Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2026
EXP016: A Novel STEAP2×CD3 BiTE with Potent Efficacy and Improved Safety for Metastatic Castration-Resistant Prostate Cancer
(SITC 2026)
- No abstract available
Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • STEAP2
1 to 1
Of
1
Go to page
1